Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis

Experimental Hematology

Volumn 35, Issue 11, 2007, Pages 1641-1646

  Williams, Donna M ^a   Kim, Ann H ^a   Rogers, Ophelia ^a   Spivak, Jerry L ^a   Moliterno, Alison R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; AGED; ARTICLE; CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; ERYTHROCYTOSIS; EXON; FEMALE; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOFIBROSIS; PHENOTYPE; POLYCYTHEMIA; POLYCYTHEMIA VERA; RECEPTORS, THROMBOPOIETIN;

EID: 35448963775     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.08.010     Document Type: Article

References (26)

1. Adamson J.W., Fialkow P.J., Murphy S., Prchal J.F., and Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 21 295 (1976) 913-916
2. Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol. 119:558-566.
3. Prchal J.F., and Axelrad A.A. Bone-marrow responses in polycythemia vera. [letter]. N Engl J Med 290 (1974) 1382
4. Temerinac S., Klippel S., Strunck E., et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95 (2000) 2569-2576
5. Moliterno A.R., Hankins W.D., and Spivak J.L. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 338 (1998) 572-580
6. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 9464 (2005) 1054-1061
7. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell l 7 (2005) 387-397
8. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 7037 (2005) 1144-1148
9. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
10. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 (2007) 459-468
11. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 (2006) e270
12. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006) 3472-3476
13. Guglielmelli P., Pancrazzi A., Bergamaschi G., et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 137 (2007) 244-247
14. Berk P.D., Goldberg J.D., Donovan P.B., Fruchtman S.M., Berlin N.I., and Wasserman L.R. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23 (1986) 132-143
15. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17 (1999) 2954-2970
16. Moliterno A.R., Williams D.M., Rogers O., and Spivak J.L. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108 (2006) 3913-3915
17. Tefferi A., Lasho T.L., Schwager S.M., et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106 (2006) 631-635
18. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
19. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
20. Dupont S., Masse A., James C., et al. The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110 (2007) 1013-1021
21. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 9501 (2005) 1945-1953
22. Percy M.J., Jones F.G., Green A.R., Reilly J.T., and McMullin M.F. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica 91 (2006) 413-414
23. Passamonti F., Vanelli L., Malabarba L., et al. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica 88 (2003) 1123-1129
24. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110 (2007) 840-846
25. Moliterno A.R., Williams D.M., Gutierrez-Alamillo L.I., Salvatori R., Ingersoll R.G., and Spivak J.L. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A 101 (2004) 11444-11447
26. Ding J., Komatsu H., Wakita A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103 (2004) 4198-4200